MNC pharma major, Novartis announced its 1QFY04 results recently. While the company has recorded a marginal growth in topline, the operating profits have seen a 25% drop. However, sharp rise in other income and lower tax provisions have helped Novartis register a 6% growth in the bottomline. In this context, let us briefly evaluate the performance of the company.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share*
P/E (at current price)
Novartis derives a major portion of its revenues from the pharma business. This segment saw a 6.6% YoY growth to Rs 810 m. The company’s strategy of revitalizing its mature product portfolio by introducing product extensions and variants seems to be paying off. New line extensions of a nasal decongestant and a Calcium Sandoz variant were key to the 19.7% growth in the OTC sales to Rs 134 m. Pricing pressure and a decline in the anti-TB business resulted in Novartis recording an 18.4% decline in the generics business to Rs 248 m.
Expenditure as a % of sales
Purchase of materials & finished goods
Despite an increase in net sales, a rise in the materials cost from 50% of revenues to 54% of revenues has resulted in Novartis recording a steep 25% decline in the operating profits. The company has incurred VRS expenditure of Rs 9 m during the current quarter. However, a sharp rise in the other income coupled with a drop in the tax provisions has enabled the company record a marginal increase in net profit. Other income has increased on account of a reversal of provision for wealth tax of Rs 21 m (1QFY03 – Nil) and interest from tax authorities of Rs 18 m (1QFY03 – Nil). Tax provisions, on the other hand, have declined due to a write back of provisions for earlier years of Rs 23 m (1QFY03 – Rs 8 m).
At Rs 245, Novartis is trading at a P/E of 11x its 1QFY04 earnings. Novartis has received shareholder’s approval for the buyback of shares upto an amount not exceeding 25% of its paid up share capital and free reserves at a price not exceeding Rs 250 per share. The company has been witnessing intense pricing pressure and declining margins in the recent times. Further, with the implementation of the new DPCO order, a major portion of its product portfolio is expected to come under DPCO cover. This could put additional pressure on the margins of the company going forward. Hence, the prospects of the company in the medium-term remain a cause of concern.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407